Initial results of phase 1/2 study CC-92480-MM-002 onCELMoD CC-92480 in combination with bortezomib (BORT)and dexamethasone (DEX) in patients with relapsed /refractory multiple myeloma (RRMM)

被引：0
|
作者：
Raab, M. -S. [1 ]
Richardson, P. G. [2 ]
Ocio, E. M. [3 ]
Raje, N. [4 ]
Gregory, T. [5 ]
White, D. [6 ,7 ]
Oriol, A. [8 ,9 ]
Sandhu, I. [10 ]
LeBlanc, R. [11 ]
Rodriguez Valdes, C. [12 ]
Trudel, S. [13 ]
Waesch, R. [14 ]
Perrot, A. [15 ]
Bahlis, N. J. [16 ]
Zhou, Z. [17 ]
Lamba, M. [17 ]
Amatangelo, M. [17 ]
Civardi, T. [18 ]
Katz, J. [17 ]
Maciag, P. [17 ]
Peluso, T. [18 ]
Dimopoulos, M. A. [19 ]
机构：
[1] Univ Klinikum Heidelberg, Heidelberg, Germany
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Hosp Univ Marques De Valdecilla IDIVAL, Santander, Spain
[4] Massachusetts Gen Hosp, Boston, MA USA
[5] Colorado Blood Canc Inst, Denver, CO USA
[6] Dalhousie Univ, Halifax, NS, Canada
[7] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[8] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
[9] Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain
[10] Univ Alberta, Edmonton, AB, Canada
[11] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada
[12] Wake Forest Baptist Hlth, Winston Salem, NC USA
[13] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[14] Univ Klinikum Freiburg, Freiburg, Germany
[15] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[16] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[17] Bristol Myers Squibb, Princeton, NJ USA
[18] Celgene Int Sarl, Bristol Myers Squibb Co, Boudry, Switzerland
[19] Alexandria Gen Hosp, Athens, Greece
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P308
引用
收藏
页码：86 / 86
页数：1
相关论文
共 50 条
  • [31] A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Hajek, Roman
    Pour, Ludek
    Ozcan, Muhit
    Sanchez, Jesus Martin
    Sanz, Ramon Garcia
    Anagnostopoulos, Achilles
    Oriol, Albert
    Cascavilla, Nicola
    Terjung, Andreas
    Lee, Yihua
    Briso, Eva M.
    Dobkowska, Edyta
    Hauns, Bernhard
    Spicka, Ivan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (05) : 435 - 442
  • [32] Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM)
    Richardson, Paul
    Mikhael, Joseph
    Usmani, Saad
    Raje, Napoor
    Bensinger, William
    Campana, Frank
    Gao, Lei
    Dubin, Franck
    Wack, Claudine
    Anderson, Kenneth C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E16 - E17
  • [33] Pomalidomide (POM), bortezomib (BORT), and dexamethasone (DEX) after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): a safety subanalysis of the phase 3 OPTIMISMM trial
    Weisel, Katja
    Dimopoulos, Meletios
    Oriol, Albert
    Beksac, Meral
    Schjesvold, Frederick
    Liberati, Anna Marina
    Lindsay, Jindriska
    White, Darrell
    San-Miguel, Jesus
    Moreau, Philippe
    Anderson, Larry D., Jr.
    Lorocca, Alessandra
    Robak, Pawel
    Vogel, Prisca
    Jiang, Ruiyun
    Grote, Lara
    Peluso, Teresa
    Richardson, Paul
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 166 - 166
  • [34] A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Jakubowiak, Andrzej J.
    Offidani, Massimo
    Pegourie, Brigitte
    De La Rubia, Javier
    Garderet, Laurent
    Laribi, Kamel
    Bosi, Alberto
    Marasca, Roberto
    Laubach, Jacob
    Mohrbacher, Ann
    Carella, Angelo Michele
    Singhal, Anil K.
    Tsao, Claire
    Lynch, Mark John
    Bleickardt, Eric W.
    Jou, Ying-Ming
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Preliminary Results of a Phase 2 Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma
    Niesvizky, Ruben
    Costa, Luciano J.
    Haideri, Nisreen A.
    Hess, Georg
    Singhal, Seema
    Spicka, Ivan
    Stadtmauer, Edward A.
    Badros, Ashraf Z.
    Raab, Marc S.
    Jakubczak, John L.
    Kim, Sindy T.
    Randolph, Sophia
    Ely, Scott A.
    Chen-Kiang, Selina
    BLOOD, 2011, 118 (21) : 1268 - 1269
  • [36] Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
    Richardson, Paul G.
    Chanan-Khan, Asher A.
    Lonial, Sagar
    Krishnan, Amrita Y.
    Carroll, Michael P.
    Alsina, Melissa
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (06) : 729 - 740
  • [37] A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).
    Jakubowiak, Andrzej J.
    White, Darrell
    Moreau, Philippe
    Facon, Thierry
    Vij, Ravi
    Kroog, Glenn Scott
    Kopit, Justin
    Singhal, Anil
    Palumbo, Antonio Pierangelo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Final results for the 1703 phase 1b/2 study of Elotuzumab (Elo) in combination with Lenalidomide (Len) and dexamethasone (dex) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Raab, M. S.
    Richardson, P. G.
    Jagannath, S.
    Moreau, P.
    Jakubowiak, A. J.
    Facon, T.
    Vij, R.
    White, D.
    Reece, D. E.
    Benboubker, L.
    Zonder, J.
    Tsao, L. C.
    Anderson, K. C.
    Bleickardt, E.
    Singhal, A. K.
    Lonial, S.
    Oncology Research and Treatment, 2015, 38 : 165 - 165
  • [39] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Victoria Mateos, Maria
    Prosper, Felipe
    Martin Sanchez, Jesus
    Ocio, Enrique M.
    Oriol, Albert
    Motllo, Cristina
    Michot, Jean-Marie
    Jarque, Isidro
    Iglesias, Rebeca
    Sole, Maria
    Martinez, Sara
    Kahatt, Carmen
    Fudio, Salvador
    Corral, Gema
    Zeaiter, Ali
    Montilla, Lola
    Ribrag, Vincent
    CANCER MEDICINE, 2023, 12 (04): : 3999 - 4009
  • [40] A phase 1/2 study of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM)
    Berenson, James R.
    Klein, Leonard M.
    Rosen, Peter J.
    Woliver, Thomas B. S.
    Eshaghlan, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345